Spots Global Cancer Trial Database for locally recurrent breast cancer
Every month we try and update this database with for locally recurrent breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) | NCT01492101 | Locally Recurre... Metastatic Brea... | NKTR-102 Treatment of Ph... | 18 Years - | Nektar Therapeutics | |
| An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO) | NCT00726661 | Breast Cancer | - | Genentech, Inc. | ||
| The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | NCT00097344 | Breast Neoplasm... Neoplasms, Horm... | Atamestane Toremifene Letrozole Aromatase inhib... Estrogen recept... Hormone therapy Endocrine thera... Antiestrogen th... | 18 Years - | Intarcia Therapeutics | |
| Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | NCT00703326 | Breast Cancer | ramucirumab (IM... docetaxel Placebo | 18 Years - | Eli Lilly and Company | |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) | NCT01492101 | Locally Recurre... Metastatic Brea... | NKTR-102 Treatment of Ph... | 18 Years - | Nektar Therapeutics | |
| Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer | NCT02064829 | Metastatic Brea... Locally Recurre... | Nab-paclitaxel IG-001 | 30 Years - | Sorrento Therapeutics, Inc. | |
| Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | NCT03786094 | Metastatic Brea... Locally Recurre... | Eribulin Balixafortide | 18 Years - | Spexis AG | |
| Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | NCT03786094 | Metastatic Brea... Locally Recurre... | Eribulin Balixafortide | 18 Years - | Spexis AG | |
| Triple Negative Breast Cancer Biomarker Study | NCT01111175 | Metastatic Brea... Triple Negative... | 18 Years - | US Oncology Research | ||
| Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and Hyperthermic Radiotherapy | NCT04878666 | Breast Cancer | 18 Years - | University Hospital Tuebingen | ||
| E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00388726 | Breast Cancer | E7389 Physician's Cho... | 18 Years - | Eisai Inc. | |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT01256762 | Locally Recurre... | Imetelstat sodi... Bevacizumab Paclitaxel | 18 Years - | Geron Corporation | |
| The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | NCT00097344 | Breast Neoplasm... Neoplasms, Horm... | Atamestane Toremifene Letrozole Aromatase inhib... Estrogen recept... Hormone therapy Endocrine thera... Antiestrogen th... | 18 Years - | Intarcia Therapeutics | |
| Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer | NCT02064829 | Metastatic Brea... Locally Recurre... | Nab-paclitaxel IG-001 | 30 Years - | Sorrento Therapeutics, Inc. | |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT01256762 | Locally Recurre... | Imetelstat sodi... Bevacizumab Paclitaxel | 18 Years - | Geron Corporation | |
| Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | NCT00044291 | Breast Neoplasm... Neoplasms, Horm... | atamestane toremifene letrozole aromatase inhib... hormone therapy endocrine thera... antiestrogen th... | 18 Years - | Intarcia Therapeutics | |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) | NCT01492101 | Locally Recurre... Metastatic Brea... | NKTR-102 Treatment of Ph... | 18 Years - | Nektar Therapeutics | |
| Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer | NCT00267553 | Breast Neoplasm... Neoplasms, Horm... | Atamestane toremifene letrozole | 18 Years - | Intarcia Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
